157 related articles for article (PubMed ID: 34257540)
1. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.
Huang RSP; Severson E; Haberberger J; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Frampton G; Owens C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Morley S; McEwan D; Holmes O; Danziger N; Cohen MB; Sathyan P; McGregor K; Reddy P; Venstrom J; Anhorn R; Alexander B; Brown C; Ross JS; Ramkissoon SH
Pathol Oncol Res; 2021; 27():592997. PubMed ID: 34257540
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
Huang RSP; Li X; Haberberger J; Sokol E; Severson E; Duncan DL; Hemmerich A; Edgerly C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Hiemenz M; Xiao J; McEwan D; Holmes O; Danziger N; Erlich R; Frampton G; Cohen MB; McGregor K; Reddy P; Cardeiro D; Anhorn R; Venstrom J; Alexander B; Brown C; Pusztai L; Ross JS; Ramkissoon SH
Oncologist; 2020 Nov; 25(11):943-953. PubMed ID: 32869930
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Jiang L; Su X; Zhang T; Yin X; Zhang M; Fu H; Han H; Sun Y; Dong L; Qian J; Xu Y; Fu X; Gavine PR; Zhou Y; Tian K; Huang J; Shen D; Jiang H; Yao Y; Han B; Gu Y
Oncotarget; 2017 Apr; 8(16):26845-26857. PubMed ID: 28460468
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
[TBL] [Abstract][Full Text] [Related]
5. Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.
Ruiz G; Enrico D; Mahmoud YD; Ruiz A; Cantarella MF; Leguina L; Barberis M; Beña A; Brest E; Starapoli S; Mendoza Bertelli A; Tsou F; Pupareli C; Coppola MP; Scocimarro A; Sena S; Levit P; Perfetti A; Aman E; Girotti MR; Arrieta O; Martín C; Salanova R
Thorac Cancer; 2024 Apr; 15(11):895-905. PubMed ID: 38456253
[TBL] [Abstract][Full Text] [Related]
6. Pan-cancer analysis of
Huang RSP; Decker B; Murugesan K; Hiemenz M; Mata DA; Li G; Creeden J; Ramkissoon SH; Ross JS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34130989
[TBL] [Abstract][Full Text] [Related]
7. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.
van de Haar J; Mankor JM; Hummelink K; Monkhorst K; Smit EF; Wessels LFA; Cuppen E; Aerts JGJV; Voest EE
Clin Cancer Res; 2024 Apr; 30(7):1307-1318. PubMed ID: 38300729
[TBL] [Abstract][Full Text] [Related]
8. Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.
Zhang XC; Cao X; Sun C; Xie Z; Guo JJ; Yang JJ; Yang XN; Dai HJ; Li SC; Xu XR; Zuo YX; Chen M; Koeppen H; He J; Kiermaier A; Shames D; Cheng G; Wu YL
Cancer Immunol Immunother; 2018 Mar; 67(3):471-481. PubMed ID: 29214427
[TBL] [Abstract][Full Text] [Related]
9. Molecular Diagnostics and Treatment Patterns in Metastatic Non-small Cell Lung Cancer Patients: Real World Evidence from Greece: LACHESIS Study.
Charpidou A; Mani M; Kokkotou E; Stournara L; Stathelou L; Antoniadou K; Argyropoulos E; Syrigos KN
Anticancer Res; 2024 May; 44(5):2063-2072. PubMed ID: 38677737
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer landscape of
Huang RSP; Murugesan K; Montesion M; Pavlick DC; Mata DA; Hiemenz MC; Decker B; Frampton G; Albacker LA; Ross JS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972391
[TBL] [Abstract][Full Text] [Related]
11. Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.
Chargin A; Morgan R; Sundram U; Shults K; Tsay EL; Ratti N; Patterson BK
Cancer Immunol Immunother; 2016 Nov; 65(11):1317-1323. PubMed ID: 27565980
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer.
Nesline MK; Subbiah V; Previs RA; Strickland KC; Ko H; DePietro P; Biorn MD; Cooper M; Wu N; Conroy J; Pabla S; Zhang S; Wallen ZD; Sathyan P; Saini K; Eisenberg M; Caveney B; Severson EA; Ramkissoon S
Oncol Ther; 2024 Mar; ():. PubMed ID: 38502426
[TBL] [Abstract][Full Text] [Related]
14. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
[TBL] [Abstract][Full Text] [Related]
15. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer.
Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB
JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.
Ricciuti B; Elkrief A; Alessi J; Wang X; Li Y; Gupta H; Muldoon DM; Bertram AA; Pecci F; Lamberti G; Di Federico A; Barrichello A; Vaz VR; Gandhi M; Lee E; Shapiro GI; Park H; Nishino M; Lindsay J; Felt KD; Sharma B; Cherniack AD; Rodig S; Gomez DR; Shaverdian N; Rakaee M; Bandlamudi C; Ladanyi M; Janne PA; Schoenfeld AJ; Sholl LM; Awad MM; Cheng ML
Clin Cancer Res; 2023 Jul; 29(13):2540-2550. PubMed ID: 37097610
[TBL] [Abstract][Full Text] [Related]
17. [Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer].
;
Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):743-752. PubMed ID: 34802204
[TBL] [Abstract][Full Text] [Related]
18. Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.
Willis C; Bauer H; Au TH; Menon J; Unni S; Tran D; Rivers Z; Akerley W; Schabath MB; Badin F; Sekhon A; Patel M; Xia B; Gustafson B; Villano JL; Thomas JM; Lubinga SJ; Cantrell MA; Brixner D; Stenehjem D
Oncotarget; 2022; 13():257-270. PubMed ID: 35111281
[TBL] [Abstract][Full Text] [Related]
19. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.
Ricciuti B; Lamberti G; Puchala SR; Mahadevan NR; Lin JR; Alessi JV; Chowdhury A; Li YY; Wang X; Spurr L; Pecci F; Di Federico A; Venkatraman D; Barrichello AP; Gandhi M; Vaz VR; Pangilinan AJ; Haradon D; Lee E; Gupta H; Pfaff KL; Welsh EL; Nishino M; Cherniack AD; Johnson BE; Weirather JL; Dryg ID; Rodig SJ; Sholl LM; Sorger P; Santagata S; Umeton R; Awad MM
J Clin Oncol; 2024 Apr; 42(11):1311-1321. PubMed ID: 38207230
[TBL] [Abstract][Full Text] [Related]
20. Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression.
Ligero M; Serna G; El Nahhas OSM; Sansano I; Mauchanski S; Viaplana C; Calderaro J; Toledo RA; Dienstmann R; Vanguri RS; Sauter JL; Sanchez-Vega F; Shah SP; Ramón Y Cajal S; Garralda E; Nuciforo P; Perez-Lopez R; Kather JN
Cancer Res Commun; 2024 Jan; 4(1):92-102. PubMed ID: 38126740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
